Acumen Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $127.88M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.33 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.48 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | Before market open | – | – | – |
Press releases
Announcements Acumen Pharmaceuticals filed with the SEC
The Potential of AβO-Directed Therapies Daniel O'Connell Chief Executive Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2026 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation May 2026 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2026 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2026 1
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation January 2026 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 2025 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2025 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation July 2025 1
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation May 2025 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2025 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 2024 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2024 1 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation May 2024 1 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation March 2024 1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation January 2024 1
Regulation FD disclosure · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference January 8, 2024 1 Dan O’Connell, CEO
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation December 2023 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 2023 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2023 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Item 14. Other Expenses of Issuance and Distribution.
Material agreement · Other events · EX-99.1 to Form 8-K
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K